Home » Stocks » CHMA

Chiasma, Inc. (CHMA)

Stock Price: $4.23 USD 0.16 (3.93%)
Updated Jan 26, 2021 10:21 AM EST - Market open
Market Cap 242.78M
Revenue (ttm) 142,000
Net Income (ttm) -67.02M
Shares Out 61.46M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $4.23
Previous Close $4.07
Change ($) 0.16
Change (%) 3.93%
Day's Open 4.07
Day's Range 4.05 - 4.29
Day's Volume 719,192
52-Week Range 2.98 - 7.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Appointment provides extensive commercial-stage public company financial leadership experience Appointment provides extensive commercial-stage public company financial leadership experience

GlobeNewsWire - 2 weeks ago

MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers

GuruFocus - 1 month ago

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), positio...

Other stocks mentioned: BHC, PRTK
Seeking Alpha - 1 month ago

Chiasma launched its first product, Mycapssa, on August 31, 2020. Mycapssa is the first product utilizing Chiasma's proprietary technology platform that enables oral version of previously inje...

Seeking Alpha - 1 month ago

Today, we revisit Chiasma for the first time in over a year. This promising small-cap name recently posted some encouraging trial results and has seen a big recent insider purchase by its CEO.

GlobeNewsWire - 2 months ago

NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercia...

GlobeNewsWire - 2 months ago

NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercia...

GlobeNewsWire - 2 months ago

91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized , controlled phase of the non-inferiority trial

GlobeNewsWire - 2 months ago

NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercia...

Seeking Alpha - 2 months ago

Chiasma's (CHMA) CEO Raj Kannan on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

L aunched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September

GlobeNewsWire - 2 months ago

NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitm...

GlobeNewsWire - 2 months ago

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

GlobeNewsWire - 3 months ago

Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer Mark Fitzpatrick to Step Down as President and Principal F...

GlobeNewsWire - 4 months ago

NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral thera...

GlobeNewsWire - 4 months ago

Chiasma advances U.S. commercial launch originally planned for fourth quarter Chiasma advances U.S. commercial launch originally planned for fourth quarter

GlobeNewsWire - 5 months ago

NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therap...

Seeking Alpha - 5 months ago

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

MYCAPSSA® U.S. commercial launch planned for the fourth quarter

GlobeNewsWire - 5 months ago

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

GlobeNewsWire - 5 months ago

-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=1...

The Motley Fool - 6 months ago

The company announced the pricing of a public offering of common stock.

GlobeNewsWire - 6 months ago

NEEDHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its ...

Zacks Investment Research - 6 months ago

Chiasma (CHMA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 6 months ago

NEEDHAM, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its ...

Seeking Alpha - 6 months ago

Chiasma's Valuation Should Be Higher Than $5-6/Share Now That Mycapssa Is FDA Approved

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Chiasma (CHMA) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Seeking Alpha - 8 months ago

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

NEEDHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late stage biopharmaceutical company focused on improving the lives of patients who face challeng...

Seeking Alpha - 10 months ago

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

FDA sets PDUFA date of June 26, 2020

GlobeNewsWire - 1 year ago

MYCAPSSA ® NDA resubmitted to FDA; PDUFA decision expected mid-2020

GlobeNewsWire - 1 year ago

NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious ch...

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious ch...

Seeking Alpha - 1 year ago

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious ch...

Zacks Investment Research - 1 year ago

Chiasma (CHMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

When we first visited all-or-nothing drug delivery concern and busted IPO Chiasma last October, it had just completed enrollment of two Phase 3 trials for the treatment of acromegaly.

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious c...

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious c...

Zacks Investment Research - 1 year ago

Chiasma (CHMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

Chiasma's (CHMA) CEO Raj Kannan on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Chiasma announced positive results from its Phase 3 CHIASMA OPTIMAL study in that all primary and secondary endpoints were met.

GuruFocus - 1 year ago

Further expanding his holdings in the health care space, billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.24% stake in biotech company C...

Seeking Alpha - 1 year ago

CHMA chart shows a strong bullish trend in the last one year, however, the stock is down strongly in the past few days after the end of profit taking session.

Benzinga - 1 year ago

Thinly-traded micro-cap biotech Chiasma Inc (NASDAQ: CHMA) is advancing strongly in reaction to a clinical trial readout from the company.

Seeking Alpha - 1 year ago

Chiasma is a small-cap biotech focusing on developing of oral formulation of the existing drug for acromegaly (octreotide) and attacking a $810m market.

Zacks Investment Research - 1 year ago

Chiasma (CHMA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Chiasma.

About CHMA

Chiasma, a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.

Industry
Biotechnology
IPO Date
Jul 16, 2015
CEO
Raj Kannan
Employees
85
Stock Exchange
NASDAQ
Ticker Symbol
CHMA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Chiasma stock is "Strong Buy." The 12-month stock price forecast is 13.20, which is an increase of 212.06% from the latest price.

Price Target
$13.20
(212.06% upside)
Analyst Consensus: Strong Buy